Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Madlaina Costa‐Scharplatz
Observed names:
Costa-Scharplatz, Madlaina,
M Costa-Scharplatz,
M. Costa-Scharplatz,
Madlaina Costa-Scharplatz
Institution:
Novartis (Sweden)
Observed institutions:
Novartis (Switzerland),
University of Nottingham,
University of Zurich,
University Hospital Zurich,
Novartis (Sweden),
Novartis (Australia),
AstraZeneca (Sweden)
show all 7
OpenAlex ID:
A5027806905
Economic burden of COPD in a Swedish cohort: the ARCTIC study
2018
·
Karin Lisspers
, Kjell Larsson
, et al.
·
International Journal of COPD
·
63
PDF
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research
2024
·
Pia R Kamstrup
, R Dermot G Neely
, et al.
·
European Journal of Preventive Cardiology
·
49
PDF
Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care
2019
·
Minna A. Korolainen
, Samu Kurki
, et al.
·
The Journal of Headache and Pain
·
42
PDF
Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank
2023
·
Paul Welsh
, Anas Al Zabiby
, et al.
·
Atherosclerosis
·
39
PDF
Recurrent Heart Failure Hospitalizations Increase the Risk of Cardiovascular and All-Cause Mortality in Patients with Heart Failure in Sweden: A Real-World Study
2021
·
Krister Lindmark
, Kurt Boman
, et al.
·
ESC Heart Failure
·
37
PDF
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting
2014
·
David Price
, Dorothy Keininger
, et al.
·
Respiratory Medicine
·
33
PDF
Implementation of Sacubitril/Valsartan in Sweden: Clinical Characteristics, Titration Patterns, and Determinants
2020
·
Michael Fu
, Ola Vedin
, et al.
·
ESC Heart Failure
·
28
PDF
Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor
2007
·
Madlaina Costa-Scharplatz
, Antoinette D.I. van Asselt
, et al.
·
Pharmacogenetics and Genomics
·
26
Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden
2021
·
Kurt Boman
, Krister Lindmark
, et al.
·
BMJ Open
·
25
PDF
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective
2008
·
Madlaina Costa-Scharplatz
, Krishnan Ramanathan
, et al.
·
Clinical Therapeutics
·
25
Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
2022
·
Michael Fu
, Aldina Pivodic
, et al.
·
Clinical Research in Cardiology
·
16
PDF
Clinical characteristics and mortality of patients with heart failure in Southern Sweden from 2013 to 2019: a population-based cohort study
2022
·
Jason Davidge
, Awais Ashfaq
, et al.
·
BMJ Open
·
14
PDF
Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden
2015
·
Madlaina Costa-Scharplatz
, Björn Ställberg
, et al.
·
Applied Health Economics and Health Policy
·
10
The economic burden of COPD in a Swedish cohort: The ARCTIC study
2016
·
Karin Lisspers
, Kjell Larsson
, et al.
·
European Respiratory Journal
·
9
Sex Differences of Lp(a) and Association With Mortality in a Primary Prevention Cohort
2025
·
Tessa M. Zeis
, Danielle Brennan
, et al.
·
JACC Advances
·
6
PDF
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States
2023
·
Ana F Fonseca
, Hannah Byrne
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
6
PDF
Cost-Effectiveness of Secukinumab Compared to Ustekinumab In Patients With Psoriasis From A Swedish Health Care Perspective
2015
·
M Costa-Scharplatz
, A Lang
, et al.
·
Value in Health
·
6
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
2017
·
Leif Bjermer
, Job F. M. van Boven
, et al.
·
Respiratory Research
·
5
PDF
Lipoprotein(a), High-Sensitivity C-Reactive Protein, and All-Cause Mortality in a Primary Prevention Cohort
2025
·
Vincent Chen
, Danielle Brennan
, et al.
·
JACC Advances
·
4
How common is elevated Lp(a) in premature ASCVD patients? A real-world study using a large us electronic health record database
2025
·
Hannah Byrne
, Sikha Sinha
, et al.
·
Atherosclerosis
·
1
The burden of coronary revascularization associated with lipoprotein(a) in patients with atherosclerotic cardiovascular disease: data from the UK Biobank
2022
·
P Welsh
, H Byrne
, et al.
·
European Heart Journal
·
1
PDF
Pcv48 - Total Annual Healthcare Costs of Heart Failure Between 2005 and 2014: a Retrospective, Population-based Study in Sweden
2018
·
K. Boman
, K. Lindmark
, et al.
·
Value in Health
·
1
Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction in Sweden
2016
·
M Costa-Scharplatz
, A Lang
, et al.
·
Value in Health
·
1
Cost-Effectiveness of Glycopyrronium Compared to Tiotropium in COPD Patients from a Swedish Societal Perspective
2013
·
M. Costa-Scharplatz
, M. Tambour
, et al.
·
Value in Health
·
1
Cv2 Cost-effectiveness of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin From a Canadian Health Care Perspective
2007
·
M Costa-Scharplatz
, B Beamer
, et al.
·
Value in Health
·
1
Show more works
View as search
Works count:
68
Citation count:
450
H-index:
12
I10-index:
13
Year
Topic
Type
